These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28319193)

  • 1. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
    Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T
    PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of JC virus serostatus stability among multiple sclerosis patients.
    Alroughani R; Akhtar S; Ahmed S; Al-Hashel J
    Mult Scler Relat Disord; 2018 Feb; 20():132-135. PubMed ID: 29414286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
    Auer M; Hegen H; Sellner J; Oppermann K; Bsteh G; Di Pauli F; Berger T; Deisenhammer F
    Brain Behav; 2019 Jul; 9(7):e01332. PubMed ID: 31168964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
    Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-JC virus seroprevalence in a Finnish MS cohort.
    Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
    Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.
    Peters J; Williamson E
    J Neurol; 2017 Dec; 264(12):2409-2412. PubMed ID: 29034436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
    Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
    Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis.
    Hegen H; Walde J; Bsteh G; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Berger T
    Front Immunol; 2018; 9():2435. PubMed ID: 30410486
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M; Borena W; Holm-von Laer D; Deisenhammer F
    J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic expression of JC virus in urine and its relationship to serostatus.
    Berger JR; Danaher RJ; Dobbins J; Do D; Miller CS
    Mult Scler Relat Disord; 2020 Jun; 41():101972. PubMed ID: 32135498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
    Aladro Y; Terrero R; Cerezo M; Ginestal R; Ayuso L; Meca-Lallana V; Millán J; Borrego L; Martinez-Ginés M; Rubio L; de Andrés C; Miralles A; Guijarro C; Rodríguez-García E; García-Dominguez JM; Muñoz-Fernández C; López de Silanes C; Gómez M; Thuissard I; Cerdán M; Palmí I; Díaz-Garzón LF; Meca-Lallana J
    J Neurol Sci; 2016 Jun; 365():16-21. PubMed ID: 27206867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-JC virus antibody titres increase over time with natalizumab treatment.
    Raffel J; Gafson AR; Malik O; Nicholas R
    Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.